Cancer Stem Cell News
Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Subscribe|Follow Us On
Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase I Clinical Trial for Acute Myeloid Leukemia
[Amphista Therapeutics Limited ] Amphista Therapeutics Limited announced dosing of the first patient in a Phase I trial for its lead candidate, AMX-883. Initiated following authorization from the US FDA, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk MDS1.
Inhibition of PHB2/PINK1-Mediated Mitophagy Potentiates Venetoclax Activity in Acute Myeloid Leukemia
[Leukemia] Investigators elucidated the role of PTEN-induced putative kinase 1 (PINK1), a key sensor of mitochondrial stress, in regulating mitophagy in leukemic cells.
Single-Cell CRISPR Screen Maps Epigenetic Regulators of Lineage Specification and Malignancies in Human HSPCs
[Cell Stem Cell] Scientists developed a massively parallel single-cell CRISPR screening platform in primary human hematopoietic stem and progenitor cells (HSPCs), profiling 322 regulators across 172,382 single-perturbed cells.
An All-Oral Triplet Regimen (Decitabine/Cedazuridine, Venetoclax, and Gilteritinib) for Newly Diagnosed and Relapsed/Refractory FLT3-Mutated AML and High-Risk MDS
[Blood Cancer Journal] In this Phase I/II study, the authors evaluated the safety and efficacy of an all-oral regimen of decitabine/cedazuridine, venetoclax, and gilteritinib in adults with FLT3-mutated AML and other myeloid malignancies.
Omicron SARS-CoV-2 Shows NRP1-Linked Susceptibility in Adipose-Derived MSCs and Alters Primitive Cord Blood CD34⁺ HSPCs
[PloS One] Scientists investigated SARS-CoV-2 variant-associated effects in adult MSCs and umbilical cord blood CD34 ⁺ hematopoietic stem and progenitor cells using in vitro exposure models.
HPSC-Derived Mesenchymal Stromal Cells Ameliorate Murine Autistic-Like Phenotypes through Activating Oxytocinergic Neurons
[Science Advances] Scientists showed that iPSC–derived MSCs alleviate anxiety, grooming, and social impairments in Shank3B knockout mice, a monogenic Autism spectrum disorder model.
Genomic Drivers of Leukemia and Blinatumomab Response in Adult Acute Lymphoblastic Leukemia – the ECOG-ACRIN E1910 Study
[Blood] Integration of genomic and clinical data suggested that the addition of blinatumomab to chemotherapy was associated with improved relapse-free and overall survival for several B cell acute lymphoblastic leukemia subtypes, including hyperdiploid, BCR::ABL1-like JAK-STAT and KMT2A-R B-ALL.
Reactivation of the Embryonic ζ-globin Gene Ameliorates Severe Forms of α-thalassemia
[Nature Genetics] Researchers identified the key cis-regulatory elements responsible for silencing the ζ-globin gene in definitive erythroid cells and subsequently developed gene-editing strategies that reactivate ζ-globin expression to therapeutically relevant levels.
Loss of Tars Induces Proteostasis Stress and Drives HSPC Exhaustion through mTORC1 Activation
[Acta Pharmacologica Sinica] Investigators found that knockout of the cytoplasmic threonyl-tRNA synthetase (Tars), which is a component of the translation machinery, caused hematopoietic stem and progenitor cell exhaustion and definitive, but not primitive, hematopoiesis defects in zebrafish.
The Expanding Therapeutic Landscape of β-Thalassaemia
[Lancet Haematology] The authors discuss advances in β-thalassaemia treatment over the past decade, including newly approved and late-stage therapies and their future implications, and highlight remaining research gaps.
Current and Future Therapies for Acute Myeloblastic Leukemia
[Journal of Hematology & Oncology] Scientists highlight promising future directions in AML, including therapies targeting RAS/MAPK signaling, emerging approaches for TP53-mutated disease, and immunotherapeutic strategies.
NCI Grant-Funded Study at Ohio State to Focus on Resistance to AML Treatment in Older Adults
[OSUCCC] A five-year, $3.46 million grant from the National Cancer Institute was awarded to The Ohio State University Comprehensive Cancer Center (OSUCCC) and the University of California San Francisco (UCSF). The grant will help researchers study why some patients with AML respond to treatment while others don't.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
